Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy and schizophrenia; NBI-1076986 to treat movement disorders; Osavampator for inadequate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback